Gainy and DriveWealth Partner to Launch Autopilot Investing for Gen Z Investors
The new offering on the Gainy platform allows users to invest in fractional shares and…
Year: 2023
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeing MALVERN, Pa., March 16, 2023…
Accelus Announces FDA 510(k) Clearance of Remi Robotic Navigation System for Use with 2D Fluoroscopy-Based Imaging System
Remi now cleared for use with most commonly used 2D and 3D imaging systems for…
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy…
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice…
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first…
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel…
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
Pharmanovia to acquire license to GHRYVELIN™from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO,…
Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma
–Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint…
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
The Company unveils brand name for its planned minoxidil hair regrowth product LOS ANGELES, March…
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) — SPR Therapeutics, a private medical device company focused…
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to…
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated…
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are…